

Role of circular RNAs in preeclampsia (Review)

HENGXUE JIANG^{1,2}, TAO MENG¹ and ZIWEI LI¹

¹Department of Obstetrics, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China;

²Department of Obstetrics and Gynecology, China Medical University, Shenyang, Liaoning 110001, P.R. China

Received October 10, 2023; Accepted June 25, 2024

DOI: 10.3892/etm.2024.12661

Abstract. Preeclampsia (PE) is a hypertensive disorder of pregnancy characterized by new-onset hypertension and proteinuria after 20 weeks of gestation, which affects 3-8% of pregnant individuals worldwide each year. Prevention, diagnosis and treatment of PE are some of the most important problems faced by obstetrics. There is growing evidence that circular RNAs (circRNAs) are involved in the pathogenesis of PE. The present review summarizes the research progress of circRNAs and then describes the expression patterns of circRNAs in PE and their functional mechanisms affecting PE development. The role of circRNAs as biomarkers for the diagnosis of PE, and the research status of circRNAs in PE are summarized in the hope of finding novel strategies for the prevention and treatment of PE.

Contents

1. Introduction
2. Expression pattern and diagnostic value of circRNAs in PE
3. Mechanisms of circRNAs involved in PE
4. Mechanisms and clinical application of circRNAs
5. Conclusion

1. Introduction

Circular RNAs (circRNAs) are covalently closed circular non-coding RNAs (ncRNAs) without a 5' cap and a 3' poly(A) tail (1). For decades, circRNAs were considered to be non-functional byproducts of mis-splicing (2,3). In recent years, circRNAs have been discovered in eukaryotes (4-8). With the maturity of sequencing technologies and algorithms, thousands of circRNAs have been identified, and experiments have confirmed that such RNAs are no longer 'splicing noise',

but functional molecules (7,9-12). CircRNAs can share the microRNA (miRNA/miR) response elements targeted by mRNA, thereby regulating the expression of mRNA (13).

In addition, circRNAs have other biological functions, such as regulating gene transcription and translation, and binding to RNA-binding proteins (9). CircRNAs can regulate transcriptional and post-transcriptional gene expression in various diseases such as lung cancer and gastric carcinoma (14). These functional circRNAs are of significance for the maintenance of normal cell functions and the occurrence and development of abnormal biological functions. In addition to participating in the regulation of epigenetic, transcriptional or post-transcriptional biological processes of various cells, circRNAs also play important roles in the signal pathways of cellular processes (15,16).

Preeclampsia (PE) is defined as new-onset hypertension after 20 weeks of gestation, accompanied by proteinuria, headache, dizziness, nausea, vomiting and epigastric discomfort (17). PE is a serious obstetric emergency worldwide, with an annual incidence of 3-8%, and is a major cause of increased maternal and neonatal morbidity and mortality (18). Therefore, understanding the pathogenesis of PE remains imperative for obstetricians. A growing body of evidence supports that the pathogenesis of PE is multifactorial, including insufficient invasive ability of trophoblasts (19), failure of spiral artery remodeling (18), abnormal immune responses (18), inflammatory responses (20) and genetic factors (21). These pathogenic mechanisms can be regulated by epigenetics (21). As a type of ncRNA, circRNAs are widely involved in gene expression, protein/RNA splicing or modification or protein-coding process (22). Abnormally expressed ncRNAs associated with PE have been identified by genome-wide analysis of placental-derived circRNA (23). Studies have confirmed that circRNA plays an important role in regulating the development and function of the placenta and the pathogenesis of PE (24,25). The abnormal placental transcriptome of PE is affected by epigenetic regulation. However, the regulation of differentially expressed genes and transcripts on the occurrence and development of PE has not been fully clarified (26). The present review summarized studies on the role of circRNAs in the pathogenesis of PE.

2. Expression pattern and diagnostic value of circRNAs in PE

At present, in the field of PE, the study of circRNAs is mainly limited to diagnostic markers and pathogenesis. Risk factors

Correspondence to: Dr Ziwei Li, Department of Obstetrics, The First Hospital of China Medical University, 155 North Nanjing Road, Shenyang, Liaoning 110001, P.R. China
E-mail: zwli@cmu.edu.cn

Key words: preeclampsia, circular RNA, microRNA, trophoblast

for PE include a history of PE in a previous pregnancy, chronic kidney disease, hypertension, diabetes, autoimmune diseases such as systemic lupus erythematosus, initial onset PE, age >40 years, inter-pregnancy interval over 10 years, a body mass index >35 kg/m², polycystic ovary syndrome and multiple pregnancies (20). However, only 30% of individuals predisposed to PE can be detected based on these risk factors (27). Due to the heterogeneous presentation of PE, potential biomarkers are required for its early detection.

Shao *et al* (28) studied the expression of circRNA in the blood of 82 pregnant individuals at 8-20 weeks of gestation and revealed that the blood concentration of circ_101222 in patients with PE was significantly higher compared with that in healthy pregnant individuals. Other studies have analyzed the expression of several mRNAs, ncRNAs and circRNAs in the plasma or placentas of individuals with PE and healthy pregnant individuals to identify potential predictive markers of PE. The expression pattern of current potential circRNAs that may serve as diagnostic markers for PE is summarized in Table I.

Among all detected markers, hsa_circ_0036877 is recognized as a potential plasma biomarker for PE (29). Two biomarkers, hsa_circ_0004904 and hsa_circ_0001855, are involved in the pathogenesis of PE by activating miRNA sponges that directly target pregnancy-associated plasma protein A (PAPP-A). This indicates that PAPP-A is present in the plasma of individuals with PE (30). However, the limitations of circRNAs as diagnostic markers must be considered. Pregnancy is a process, and the level of molecular expression in the placenta dynamically changes. More detailed grouping and long-term studies are needed to determine the time point for screening circRNA as a diagnostic marker.

3. Mechanisms of circRNAs involved in PE

PE is a hypertensive disorder (31,32). Unfortunately, the etiology and pathogenesis of PE are still far from clear. However, accumulating evidence confirms that impaired spiral artery remodeling, placental dysfunction and insufficient trophoblast invasion may play critical roles in the development and progression of PE (33-35). Furthermore, extensive or shallow invasion of extravillous trophoblasts (EVTs) at the maternal-fetal interface has been identified as a major cause of placental failure, ultimately leading to PE (36,37). Restricted migratory activity of EVT in the maternal decidua has been shown to impede trophoblast function, leading to PE (38). Some studies have investigated the pathogenesis of PE from the perspective of placenta (39,40). A large number of recent studies have shown that a variety of ncRNAs are associated with the pathogenesis of pregnancy disorders (41-45).

From the perspective of pathogenesis, abnormal placental development is one of the main causes of PE. Zhou *et al* (46) have revealed that circRNA_3286, circRNA_5593 and circRNA_3800 are downregulated in placental tissues of individuals with PE compared with healthy pregnant individuals. Melchiorre *et al* (39) have investigated the distribution of circRNAs in the placental tissues of individuals with PE and explored the potential impact of circRNA dysregulation on the progression of PE. A total of 300 circRNAs that are differentially expressed between individuals with PE and healthy

pregnant individuals were identified. Reverse transcription-quantitative PCR results showed that hg38_circ_0014736 and hsa_circ_0015382 are highly upregulated, and hsa_circ_0007121 is downregulated in all patients with PE. The data showed that these three circRNAs are significantly associated with the regulation of transcription, proliferation, hypoxia response and protein binding (47). The studies on the role of circRNAs in the pathogenesis of PE are summarized in Table II, which is helpful to explore novel strategies for the treatment of PE.

In recent decades, researchers have confirmed that circRNAs are involved in a variety of diseases (48). However, to the best of our knowledge, there have been few studies on the role of circRNAs in the pathogenesis of PE (49-51). The different mechanisms are described in detail below.

Roles of circRNAs in regulating migration and invasion of trophoblasts. Insufficient invasion and migration abilities of trophoblasts are one of the major causes of PE (42,52). Studies have shown that circRNAs can affect the invasion and migration abilities of trophoblasts (53,54). Hsa_circ_0111277 spliced from PAPP-2A is highly expressed in the placentas of patients with PE. The expression level of Hsa_circ_0111277 is proportional to the placental weight and urinary protein level, suggesting that it may be involved in PE (55). Subsequently, an *in vitro* experiment has demonstrated that Hsa_circ_0111277 regulates the Notch-1 signaling pathway through the miR-494/high-temperature requirement-A serine peptidase 1 axis, thereby inhibiting the migration and invasion of HTR-8/Svneo and JEG-3 cells (55). Notch-1 signaling pathway play an important role in the migration and invasion of trophoblasts, decreased activity of which can significantly inhibit the invasive ability of trophoblasts (30,56).

However, hsa_circ_0002814 is downregulated in the placentas of individuals with PE. Overexpressed hsa_circ_0002814 elevates Notch-1 expression by suppressing miR-21 (57), which has also been shown to bind FUS protein, thus increasing soluble fms-like tyrosine kinase 1 (sFlt-1) and VEGF protein (58). Hsa_circ_0008726 is highly expressed in the plasma and placentas of patients with PE (59). It regulates LIM homeobox transcription factor family (LHX6) and RING1 and YY1-binding protein (RYBP) by adsorbing miR-1290 and miR-345-3p, respectively, and regulates the migration and invasion abilities of trophoblasts (60,61). Hsa_circ_0007121 mediates the progression of PE through the miR-182-5p/placental growth factor (62). CircLRRK1 has been identified to inhibit trophoblast proliferation, migration and invasion through the miR-223-3p/PI3K/AKT axis (12).

Involvement of circRNAs in the regulation of epithelial-mesenchymal transition of trophoblasts. Epithelial-mesenchymal transition (EMT) is a characteristic process during which polarized epithelial cells transform into a mesenchymal phenotype, including the changes in migration and invasion abilities (63). The EMT of trophoblasts is considered to be one of the steps before efficient spiral artery remodeling (64,65). Hsa_circ_0006772 is upregulated in the placentas of individuals with PE compared with that in the placentas of healthy pregnant individuals. Overexpressed hsa_circ_0006772 increases the expression of E-cadherin protein

Table I. Diagnostic values of circRNAs in PE.

ID	Gene symbol	Expression	Sample type	Area under ROC curve	Sensitivity	Specificity	(Refs.)	Study year
hsa_circ_0007121	-	Downregulated	Plasma	0.72	0.77	0.70	(47)	2018
hsa_circ_0036877	FURIN	Downregulated	Plasma	0.85	0.85	0.73	(29)	2018
hsa_circ_0055724	ANKRD36	Downregulated	Plasma	-	-	-	(139)	2022
hsa_circ_0003496	UBAP2	Downregulated	Plasma	-	-	-	(131)	2021
hsa_circ_0002814	HERC2	Downregulated	Plasma	-	-	-	(80)	2022
hsa_circ_0003286	GTF2H2B	Downregulated	Plasma	-	-	-	(140)	2018
hsa_circ_0004904	POLE2	Upregulated	Plasma	-	-	-	(30)	2018
hsa_circ_0001855	RNF38	Upregulated	Plasma	0.62	0.53	0.70	(30)	2018
hsa_circ_0029601	TPTE2	Upregulated	Plasma	0.87	0.71	0.80	(141)	2016
hsa_circ_0025992	SLC38A2	Upregulated	Plasma	0.81	0.54	0.93	(142)	2021
hsa_circ_0001326	PHLDB2	Upregulated	Placenta	0.79	-	-	(21)	2021
hsa_circ_0008726	DNAJB6	Upregulated	Plasma	-	-	-	(143)	2022
hsa_circ_0004904	POLE2	Upregulated	Plasma	-	-	-	(144)	2021
hsa_circ_0013301	HIAT1	Upregulated	Plasma	-	-	-	(145)	2021
hsa_circ_0007885	BRAP	Upregulated	Plasma	0.71	0.63	0.76	(64)	2022
hsa_circ_0058152	FN1	Upregulated	Plasma	0.78	0.87	0.56	(146)	2022

circRNA, circular RNA; PE, preeclampsia.

and decreases the expression of Vimentin protein, which are EMT-related protein markers. It sponges miR-762 to inhibit the miR-762 expression and elevates the level of Grhl2 protein, an EMT-related transcriptional factor (11). These findings demonstrate that circTNRC18 inhibits EMT of trophoblasts, suggesting that it may be involved in the progression of PE.

Regulation of cell proliferation and apoptosis by circRNAs. PAPP-A, a key regulator of insulin-like growth factor bioavailability, is essential for normal fetal development (66). Hsa_circ_0015382 is also derived from the splicing of PAPP-2A transcript, which is upregulated in the placentas of individuals with PE (67). By regulating the expression of tissue factor pathway inhibitor 2 (TFPI2), hsa_circ_0015382 not only inhibits the migration and invasion abilities of trophoblasts, but also inhibits the proliferation of trophoblasts and promotes their apoptosis (68). Hsa_circ_0001326 is highly expressed in the placentas of individuals with PE, which can modulate the level of p27 Kip1 by absorbing miR-186-5p (12). Overexpressed hsa_circ_0001326 significantly upregulates p27 Kip1, cleaves caspase 3 and downregulates cyclin-dependent kinase 2 (CDK2) and cyclin E1, suggesting decreased viability and proliferation of trophoblasts. While hsa_circ_0001326 induces G₀/G₁ cell cycle arrest is attenuated in the case of p27 Kip1 knockdown (69). These findings show that hsa_circ_0001326 may be involved in the progression of PE. Hsa_circ_0017068, as a post-transcriptional regulator of X-linked inhibitor of apoptosis protein, has been reported to regulate the proliferation, cell cycle and apoptosis of trophoblasts by targeting miR-330-5p (51).

Other functions of circRNAs involved in PE. In one study, a microarray analysis was performed using placental tissue

from pregnant individuals with PE (70), the results of which revealed that hsa_circRNA_100782, hsa_circRNA_102682 and hsa_circRNA_104820 are highly upregulated in PE. The identified circRNAs have multiple binding sites for miRNA-17, indicating that these circRNAs can regulate the expression of miRNA-17 in human placental tissues. A previous study showed that increased expression of miRNA-17 in the placenta contributes to the development of PE by promoting trophoblast invasion (71). Therefore, the differential expression of circRNAs in the placenta may lead to the upregulation of miRNA-17 by activating the miRNA sponge, thereby enhancing the pathogenesis of PE. MiRNA-17 has been introduced as an angiogenesis-related miRNA and is highly expressed in PE (72).

The placentas of individuals with PE show endothelial cell swelling called endotheliosis and microvascular obstruction (73). PE has been implicated in altered expression of angiogenic and antiangiogenic factors, sFlt-1 or sVEGFR1, which is overproduced by the early placenta and secreted into the maternal peripheral blood. In the maternal bloodstream, it is considered to bind and neutralize VEGF and PlGF, a member of the VEGF subfamily, with high affinity, which results in a reduction of VEGF and PlGF in maternal blood and the disruption of VEGF signaling in endothelial cells due to reduced number of bound VEGF receptors (74-76). In conclusion, the disturbed balance between PlGF and sFlt-1 is one of the causes of PE. Hsa_circ_0063517 has a decreased expression in the placentas of patients with PE, and its knockdown reduces the expression of endothelin B receptor, VEGFA and VEGFR2 in HUVEC-12 and HMEC-1 cells by sponging miR-31-5p (77), which suggests that hsa_circ_0063517 is involved in the angiogenesis of placenta.

Table II. Mechanism studies of circRNAs in preeclampsia.

circRNA ID	Gene symbol	Expression	Cell	Target	Function	(Refs.)	Study year
hsa_circ_0055724	ANKRD36	Downregulated	Trophoblast	N-cadherin	Proliferation; migration; invasion	(147)	2022
hsa_circ_0003496	UBAP2	Downregulated	Trophoblast	FOXO1	Proliferation; migration	(60)	2021
hsa_circ_0002814	HERC2	Downregulated	Trophoblast	Notch-1, CPEB2, FUS/VEGF	Proliferation; invasion	(58)	2022
hsa_circ_0088227	PAPPA	Downregulated	Trophoblast	HOXA7	Proliferation; migration; invasion	(143)	2022
hsa_circ_0000284	HIPK3	Downregulated	Trophoblast	-	Migration; invasion; proliferation; angiogenesis	(148)	2019
hsa_circ_0003286	GTF2H2B	Downregulated	Trophoblast	-	Invasion	(46)	2018
hsa_circ_0032962	SMEK1	Downregulated	Trophoblast	PBX3	proliferation; migration; invasion; EMT	(143)	2021
hsa_circ_0005734	FAM53B	Downregulated	Trophoblast	KCMF1	Proliferation; migration; invasion	(149)	2022
hsa_circ_0017068	B3GALNT2	Downregulated	Trophoblast	XIAP	Proliferation; cell cycle; apoptosis	(150)	2022
hsa_circ_0063517	RANGAP1	Downregulated	Vascular endothelial cell	ETBR	Proliferation; migration; angiogenesis	(80)	2020
hsa_circ_0001326	PHLDB2	Upregulated	Trophoblast	p27 Kip1	Proliferation; migration	(12)	2021
hsa_circ_0001326	PHLDB2	Upregulated	Trophoblast	IL16	Proliferation; EMT; migration; invasion.	(151)	2021
hsa_circ_0008726	DNAJB6	Upregulated	Trophoblast	LHX6	Proliferation; migration; invasion	(143)	2022
hsa_circ_0008726	DNAJB6	Upregulated	Trophoblast	RYBP	Migration; invasion; EMT	(60)	2021
hsa_circ_0004904	POLE2	Upregulated	Trophoblast	ATG12, FUS/VEGF	Proliferation; invasion; autophagy	(144)	2021
hsa_circ_0007445	OPHN1	Upregulated	Trophoblast	THBS2	Proliferation; migration; invasion	(57)	2022
hsa_circ_0007611	FAM193B	Upregulated	Trophoblast	IL1RAP	Proliferation; angiogenesis	(152)	2022
hsa_circ_0007885	BRAP	Upregulated	Trophoblast	HIF-2 α , sFLT1	Proliferation; invasion	(61)	2022
hsa_circ_0058152	FN1	Upregulated	Trophoblast	ATF2	Proliferation; migration; invasion; apoptosis	(149)	2022
hsa_circ_0015382	PAPPA2	Upregulated	Trophoblast	TFPI2	Proliferation; migration; invasion; EMT; apoptosis; cell cycle	(94)	2021
hsa_circ_0088196	TNC	Upregulated	Trophoblast	ABL1	Migration; invasion	(149)	2022
hsa_circ_0088196	TNC	Upregulated	Trophoblast	LIF, jak-stat	-	(153)	2019
hsa_circ_0000566	VRK1	Upregulated	Trophoblast	PTEN, Akt	Migration; invasion; EMT	(154)	2021
hsa_circ_0085296	RIMS2	Upregulated	Trophoblast	THBS2	Proliferation; migration; invasion; angiogenesis	(58)	2022
hsa_circ_0085296	RIMS2	Upregulated	Trophoblast	E-cadherin	Proliferation; migration; invasion	(80)	2020
hsa_circ_0111277	PAPPA2	Upregulated	Trophoblast	HTRA1, Notch-1	Migration; invasion	(55)	2020
hsa_circ_0011460	AK2	Upregulated	Trophoblast	PGT	-	(51)	2019
hsa_circ_0011460	AK2	Upregulated	Trophoblast	THBS2	Proliferation; migration; invasion	(145)	2021

Table II. Continued.

circRNA ID	Gene symbol	Expression	Cell	Target	Function	(Refs.)	Study year
hsa_circ_0011460	AK2	Upregulated	Trophoblast	HTRA1	Proliferation; migration; invasion	(94)	2021
hsa_circ_0006772	TNRC18	Upregulated	Trophoblast	Grhl2	Migration; EMT	(154)	2019

circRNA, circular RNA; LHX6, LIM homeobox transcription factor family; RYBP, RING1 and YY1-binding protein; EMT, epithelial-mesenchymal transition; TFPI2, tissue factor pathway inhibitor 2; XIAP, X-linked inhibitor of apoptosis protein; ETBR, endothelin B receptor.

Circ_0001438 aggravates human villous trophoblast dysfunction by mediating the miR-942/NLRP3 axis (78). It has been reported that circCRAMP1L, circSFXN1 and circ_0085296 are involved in the pathogenesis of PE to varying degrees (50,79,80).

4. Mechanisms and clinical application of circRNAs

Although the functions of most circRNAs remain unclear, only a small fraction of identified circRNAs have been studied for their biological significance (81-85). A study has shown that circRNAs have binding sites for microRNAs and RNAs, and can act as RNA sponges to regulate the expression levels of target genes (86). The most representative circRNA is ciRS-7, which contains >70 conserved binding sites for miR-7 (87-89). A study has shown that circCDR1as and circMTO1 bind to miR-7 and miR9, respectively, and affect gene regulation, thereby indirectly suppressing or stimulating tumors (90). In addition, subsequent studies have also demonstrated the presence and importance of ciRS-7 as a miR-7 sponge in a number of pathophysiological processes, such as insulin secretion, myocardial infarction, hepatocellular carcinoma and gastric cancer progression (88,91-93). Based on the aforementioned theory, artificial sponge technology is a method of manufacturing molecules that can specifically bind to target miRNAs so that they can specifically adsorb target miRNAs. According to the partial base sequence of the target miRNA, circRNAs are artificially processed, then packaged with plasmids and transfected into cells or tissues, while circRNA acts as a miRNA 'sponge' to adsorb a large number of target miRNAs (64). Fan *et al* (94) found that the expression of circNR3C2 significantly enhances the tumor suppressive effect of HRD1 by sponging miR-513a-3p.

CircRNAs can also regulate biological processes by binding to proteins such as transcription factors. After binding to peccadillo homolog 1, circANRIL affects exonuclease-mediated pre-ribosomal (r)RNA processing and ribosome biogenesis (95). Circ-Foxo3 binds to CDK2 and cyclin-dependent kinase inhibitor 1 to form a ternary complex, thereby inhibiting the function of CDK2 and blocking cell cycle progression (10,96). Circ-Foxo3 also has a high binding affinity to anti-aging inhibitor of DNA binding 1, transcription factor E2F1 and anti-stress proteins FAK and HIF1a, and retains them in the cytoplasm, leading to increased cellular senescence (10). Circ-poly(A)-binding protein nuclear 1 (PABPN1) binds to HuR, thus preventing HuR from binding

to PABPN1 mRNA to reduce PABPN1 translation (61,97). However, not all circRNAs that interact with proteins inhibit protein function. Ectopic circ-Amotl1 interacts with and stabilizes the nuclear oncogene c-myc, thereby upregulating c-myc targets and promoting tumorigenesis (98,99).

An early study by Chen and Sarnow in 1995 (100) demonstrated that synthetic circRNAs can recruit the 40S ribosomal subunit and initiate the translation of detectable peptides in human cells through internal entry sites. Studies have shown that, if an internal ribosome entry site (IRES) is inserted upstream of the start codon, whether *in vivo* or *in vitro*, circRNAs that are similar to certain RNAs without a 5' cap structure and a 3' (polyA) tail structure can be translated into proteins (101,102). Although IRES-mediated translation was first discovered in RNA and DNA viruses, it has subsequently been discovered in mRNAs such as immunoglobulin heavy chain binding protein mRNA, fibroblast growth factor and VEGF mRNA (103-105).

At present, several translated circRNAs have been identified to play key roles in human diseases, especially cancer. In gliomas, circSHPRH, produced by the SNF2 histone linker PHD RING helicase (SHPRH) gene, encodes a novel 146-amino acid protein (SHPRH-146aa), which exhibits inhibitory activity during tumorigenesis and glioma activity and also serves as a biomarker (106-108). Another glioma study revealed that circLINC-PINT is derived from a long intergenic non-coding RNA p53-induced transcript (LINC-PINT), which encodes an 87-amino acid peptide (PINT87aa). It interacts with the PAF1 complex in the nucleus to inhibit the transcriptional elongation of multiple oncogenes, thus playing a tumor suppressor role in the control of cell proliferation and tumorigenesis (106).

There are also studies showing that circ-F-box and WD-repeat domain containing 7 (FBXW7) can inhibit the development of glioma (109,110). CircFBXW7 is produced by the tumor suppressor E3 ligase FBXW7, which encodes a 185 amino acid peptide (FBXW7-185aa), that plays the role of a tumor suppressor in glioma (111). Another recent study showed that FBXW7-185aa can inhibit the proliferation and migration of triple-negative breast cancer cells by increasing FBXW7 abundance and inducing c-Myc degradation (112).

In hepatocellular carcinoma, GSK3 β -induced phosphorylation and degradation of β -catenin lead to activation of the Wnt pathway, which is associated with poor hepatocellular carcinogenesis and prognosis (113,114). In circBase, circ β -catenin is the only isoform that can be expressed in hepatocellular

carcinoma (115). Circ β -catenin produces a 370 amino acid peptide (β -catenin-370aa), and can promote the growth of liver cancer cells by activating the Wnt pathway (116,117).

Other studies have confirmed that circRNAs can activate the encoded protein through the m6A mechanism (118,119). The modification of m6A is completed by methyltransferase complexes such as methyltransferase-like (METTL)-3, METTL-14, Wilms Tumor 1-associated protein, RNA-binding motif protein 15 and zinc finger CCH domain-containing protein 13 (4,120-124). Various internal or external factors, such as cell type, developmental stage, nutrient supply, circadian rhythm and environmental stresses initiate m6A translation (125). The 5'UTR m6A residue can directly recruit eukaryotic initiation factor 3, which is sufficient to recruit the 43S pre-initiation complex and bypass the m7G capping requirement to initiate translation, thus enabling translation initiation in the absence of the cap-binding factor eIF4E model (126).

Unlike conventional forward splicing, circRNAs originate from the same precursor as linear RNA transcripts, which is formed by a process called back splicing. Back-splicing creates a covalently closed loop that is characterized by a non-linear back-splicing junction between the splice donor and upstream splice acceptor, and it lacks a 5' cap and a 3' poly(A) tail (127). Due to this structural feature, circRNA can resist digestion by nucleic acid ribozymes (such as RNase R) and is more difficult to be degraded by exonuclease, so it is more stable compared with linear RNAs, with a longer half-life of up to 10 times that of linear RNA (128). These attributes make circRNA a potential biomarker for disease diagnosis and prognosis (85). CircRNA is stable and not easy to be degraded in blood and exosomes. It can be quantitatively detected by reverse transcription followed by qPCR (85). At the same time, compared with the complex antigen-antibody reaction and unclear parameters of protein detection, circRNAs are always expressed in a tissue- or cell-specific manner and can be detected by qPCR and *in situ* hybridization, which makes circRNA an ideal molecule for clinical diagnosis or prognosis detection of diseases, with landmark significance (1,7,129-131).

CircRNAs have been implicated in a variety of diseases, such as bone-osteosarcoma, colon-colorectal adenocarcinoma, kidney-renal cell carcinoma, liver-hepatocellular carcinoma, lung-lung adenocarcinoma and stomach-gastric adenocarcinoma (132). Due to the observed association between circRNA abundance and cancer, circRNA may serve as a cancer biomarker with good diagnostic performance (133). A study has also shown that circRNAs are present in human body fluids such as saliva, plasma, plasma and exosomes at relatively high steady-state levels, making them candidate biomarkers for non-invasive liquid biopsies (127). Zhang *et al* (79) found that circSATB2 is highly expressed in non-small cell lung cancer cells and tissues. CircSATB2 is highly expressed in plasma exosomes of patients with lung cancer with high sensitivity and specificity for clinical detection, and is associated with lung cancer metastasis (134). Wang *et al* (134) found that circRNA-002178 is detectable in the plasma exosomes of patients with lung adenocarcinoma (LUAD) and can be used as a biomarker for early diagnosis of LUAD. These studies provide a certain basis for the use of circRNAs as molecular

markers for disease diagnosis and provide a new method for clinical screening of diseases.

5. Conclusion

PE is defined as new-onset hypertension after 20 weeks of gestation, so early diagnosis is crucial for PE. Due to the current lack of sufficient data or the heterogeneity of the recruited population, circRNA is not sufficient as a marker for PE monitoring and screening. Given the molecular advantages of circRNAs over linear RNAs, studies on circRNAs are more focused on possible screening purposes. Although some studies have reported the possible screening performance of circRNAs in the first or second trimester of pregnancy, a single circRNA has not been successfully used in any PE screening program (135-137). One study has found that the area under the curve (AUC) of plasma hsa_circ_0001855 is 0.62. While using the plasma protein PAPP-A in combination with hsa_circ_0001855 and hsa_circ_0004904, the AUC increases to 0.94, with a sensitivity of 0.87 and a specificity of 0.97 (30). In another study combining plasma hsa_circ_0007885 level, plasma sFLT1 level and abnormal uterine artery pulsatility index (UtA-PI), the AUC is 0.85, and the sensitivity and specificity are 0.80 and 0.86, respectively (138). The predictive power for PE is far stronger compared with any previous single molecular or ultrasound data (61). In summary, circRNAs can be combined with some specific molecules or clinical examination data such as PPAP-As, sFlt-1 and UtA-PI for prediction as a new strategy for early clinical diagnosis of PE.

The present review summarizes the study progress of circRNAs in PE in recent years. The endogenous competitive mechanism of circRNAs occupies the majority, which is of help for understanding the pathogenesis of PE. However, the research on circRNAs has only revealed the tip of the iceberg, such as RNA-binding proteins and encoded proteins, which have potential for the prevention and treatment of PE. With the development of sequencing technology, more circRNAs will be discovered and new methods will be used to study PE. We hope that this review has provided help for the diagnosis and treatment of PE.

Acknowledgements

Not applicable.

Funding

This work was supported by the National Natural Science Foundation (grant no. 81871173).

Availability of data and materials

Not applicable.

Authors' contributions

HJ contributed significantly to analysis and manuscript preparation, performed the data analyses and wrote the manuscript. ZL and TM revised the manuscript. All authors reviewed the

manuscript. Data authentication is not applicable. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Smid M, Wilting SM, Uhr K, Rodríguez-González FG, de Weerd V, Prager-Van der Smissen WJC, van der Vlucht-Daane M, van Galen A, Nik-Zainal S, Butler A, *et al*: The circular RNome of primary breast cancer. *Genome Res* 29: 356-366, 2019.
- Cocquerelle C, Mascres B, Hétiu D and Bailleul B: Mis-splicing yields circular RNA molecules. *FASEB J* 7: 155-160, 1993.
- Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB and Kjems J: The biogenesis, biology and characterization of circular RNAs. *Nat Rev Genet* 20: 675-691, 2019.
- Schwartz S, Mumbach MR, Jovanovic M, Wang T, Maciag K, Bushkin GG, Mertins P, Ter-Ovanesyan D, Habib N, Cacchiarelli D, *et al*: Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites. *Cell Rep* 8: 284-296, 2014.
- Ivanov A, Memczak S, Wyler E, Torti F, Porath HT, Orejuela MR, Piechotta M, Levanon EY, Landthaler M, Dieterich C and Rajewsky N: Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. *Cell Rep* 10: 170-177, 2015.
- Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF and Sharpless NE: Circular RNAs are abundant, conserved, and associated with ALU repeats. *RNA* 19: 141-157, 2013.
- Salzman J, Chen RE, Olsen MN, Wang PL and Brown PO: Cell-type specific features of circular RNA expression. *PLoS Genet* 9: e1003777, 2013.
- Westholm JO, Miura P, Olson S, Shenker S, Joseph B, Sanfilippo P, Celniker SE, Graveley BR and Lai EC: Genome-wide analysis of drosophila circular RNAs reveals their structural and sequence properties and age-dependent neural accumulation. *Cell Rep* 9: 1966-1980, 2014.
- Maass PG, Glazar P, Memczak S, Dittmar G, Hollfinger I, Schreyer L, Sauer AV, Toka O, Aiuti A, Luft FC and Rajewsky N: A map of human circular RNAs in clinically relevant tissues. *J Mol Med (Berl)* 95: 1179-1189, 2017.
- Du WW, Yang W, Chen Y, Wu ZK, Foster FS, Yang Z, Li X and Yang BB: Foxo3 circular RNA promotes cardiac senescence by modulating multiple factors associated with stress and senescence responses. *Eur Heart J* 38: 1402-1412, 2017.
- Ruan H, Xiang Y, Ko J, Li S, Jing Y, Zhu X, Ye Y, Zhang Z, Mills T, Feng J, *et al*: Comprehensive characterization of circular RNAs in ~1000 human cancer cell lines. *Genome Med* 11: 55, 2019.
- Tang R, Zhang Z and Han W: CircLRRK1 targets miR-223-3p to inhibit the proliferation, migration and invasion of trophoblast cells by regulating the PI3K/AKT signaling pathway. *Placenta* 104: 110-118, 2021.
- Wei L, Wang S, Zhang K, Tan S, Xin J, Yuan Q, Xu H, Xu X, Liang Q, Christiani DC, *et al*: Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies. *Mol Cancer* 20: 13, 2021.
- Barrett SP and Salzman J: Circular RNAs: Analysis, expression and potential functions. *Development* 143: 1838-1847, 2016.
- Gong W, Xu J, Wang Y, Min Q, Chen X, Zhang W, Chen J and Zhan Q: Nuclear genome-derived circular RNA circPUM1 localizes in mitochondria and regulates oxidative phosphorylation in esophageal squamous cell carcinoma. *Signal Transduct Target Ther* 7: 40, 2022.
- Deng M and Zou W: Noncoding RNAs: Novel targets for opioid tolerance. *Curr Neuropharmacol* 21: 1202-1213, 2023.
- Correction to: Preeclampsia: Pathophysiology, challenges, and perspectives. *Circ Res* 126: e8, 2020.
- Magee LA, Nicolaides KH and von Dadelszen P: Preeclampsia. *N Engl J Med* 386: 1817-1832, 2022.
- Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. *Obstet Gynecol* 135: e237-e260, 2020.
- Ma'ayeh M and Costantine MM: Prevention of preeclampsia. *Semin Fetal Neonatal Med* 25: 101123, 2020.
- Liu J, Song G, Zhao G and Meng T: Epicardial adipose tissue thickness as a potential predictor of pre-eclampsia. *Pregnancy Hypertens* 23: 87-90, 2021.
- Wu P, Mo Y, Peng M, Tang T, Zhong Y, Deng X, Xiong F, Guo C, Wu X, Li Y, *et al*: Emerging role of tumor-related functional peptides encoded by lncRNA and circRNA. *Mol Cancer* 19: 22, 2020.
- Liu S, Xie X, Lei H, Zou B and Xie L: Identification of Key circRNAs/lncRNAs/miRNAs/mRNAs and pathways in preeclampsia using bioinformatics analysis. *Med Sci Monit* 25: 1679-1693, 2019.
- Gong S, Gaccioli F, Dopierala J, Sovio U, Cook E, Volders PJ, Martens L, Kirk PDW, Richardson S, Smith GCS and Charnock-Jones DS: The RNA landscape of the human placenta in health and disease. *Nat Commun* 12: 2639, 2021.
- Sun N, Qin S, Zhang L and Liu S: Roles of noncoding RNAs in preeclampsia. *Reprod Biol Endocrinol* 19: 100, 2021.
- Deng J, Zhao HJ, Zhong Y, Hu C, Meng J, Wang C, Lan X, Wang X, Chen ZJ, Yan J, *et al*: H3K27me3-modulated Hofbauer cell BMP2 signalling enhancement compensates for shallow trophoblast invasion in preeclampsia. *EBioMedicine* 93: 104664, 2023.
- Saleem S, McClure EM, Goudar SS, Patel A, Esamai F, Garces A, Chomba E, Althabe F, Moore J, Kodkany B, *et al*: A prospective study of maternal, fetal and neonatal deaths in low- and middle-income countries. *Bull World Health Organ* 92: 605-612, 2014.
- Shao Y, Tao X, Lu R, Zhang H, Ge J, Xiao B, Ye G and Guo J: Hsa_circ_0065149 is an indicator for early gastric cancer screening and prognosis prediction. *Pathol Oncol Res* 26: 1475-1482, 2020.
- Hu X, Ao J, Li X, Zhang H, Wu J and Cheng W: Competing endogenous RNA expression profiling in pre-eclampsia identifies hsa_circ_0036877 as a potential novel blood biomarker for early pre-eclampsia. *Clin Epigenetics* 10: 48, 2018.
- Jiang M, Lash GE, Zhao X, Long Y, Guo C and Yang H: CircRNA-0004904, CircRNA-0001855, and PAPP-A: Potential novel biomarkers for the prediction of preeclampsia. *Cell Physiol Biochem* 46: 2576-2586, 2018.
- Nakashima A, Cheng SB, Kusabiraki T, Motomura K, Aoki A, Ushijima A, Ono Y, Tsuda S, Shima T, Yoshino O, *et al*: Endoplasmic reticulum stress disrupts lysosomal homeostasis and induces blockade of autophagic flux in human trophoblasts. *Sci Rep* 9: 11466, 2019.
- Chappell LC, Cluver CA, Kingdom J and Tong S: Pre-eclampsia. *Lancet* 398: 341-354, 2021.
- Velicky P, Windsperger K, Petroczi K, Pils S, Reiter B, Weiss T, Vondra S, Ristl R, Dekan S, Fiala C, *et al*: Pregnancy-associated diamine oxidase originates from extravillous trophoblasts and is decreased in early-onset preeclampsia. *Sci Rep* 8: 6342, 2018.
- Bos M, Baelde HJ, Bruijn JA, Bloemenkamp KW, van der Hoorn MP and Turner RJ: Loss of placental thrombomodulin in oocyte donation pregnancies. *Fertil Steril* 107: 119-129.e5, 2017.
- Ramsay JE, Ferrell WR, Crawford L, Wallace AM, Greer IA and Sattar N: Divergent metabolic and vascular phenotypes in pre-eclampsia and intrauterine growth restriction: Relevance of adiposity. *J Hypertens* 22: 2177-2183, 2004.
- Tong C, Feng X, Chen J, Qi X, Zhou L, Shi S, Kc K, Stanley JL, Baker PN and Zhang H: G protein-coupled receptor 30 regulates trophoblast invasion and its deficiency is associated with preeclampsia. *J Hypertens* 34: 710-718, 2016.
- Wu L, Song WY, Xie Y, Hu LL, Hou XM, Wang R, Gao Y, Zhang JN, Zhang L, Li WW, *et al*: miR-181a-5p suppresses invasion and migration of HTR-8/SVneo cells by directly targeting IGF2BP2. *Cell Death Dis* 9: 16, 2018.
- Wang G, Zhang Z, Chen C, Zhang Y and Zhang C: Dysfunction of WNT4/WNT5A in deciduas: possible relevance to the pathogenesis of preeclampsia. *J Hypertens* 34: 719-727, 2016.

39. Melchiorre K, Giorgione V and Thilaganathan B: The placenta and preeclampsia: Villain or victim? *Am J Obstet Gynecol* 226 (2S): S954-S962, 2022.
40. Zhou W, Wang H, Yang Y, Guo F, Yu B and Su Z: Trophoblast cell subtypes and dysfunction in the placenta of individuals with preeclampsia revealed by single-cell RNA sequencing. *Mol Cells* 45: 317-328, 2022.
41. Huang Z, Du G, Huang X, Han L, Han X, Xu B, Zhang Y, Yu M, Qin Y, Xia Y, *et al*: The enhancer RNA lnc-SLC4A1-1 epigenetically regulates unexplained recurrent pregnancy loss (URPL) by activating CXCL8 and NF- κ B pathway. *EBioMedicine* 38: 162-170, 2018.
42. Jiao S, Wang SY and Huang Y: LncRNA PRNCR1 promoted the progression of eclampsia by regulating the MAPK signal pathway. *Eur Rev Med Pharmacol Sci* 22: 3635-3642, 2018.
43. Wang XQ, Li Y, Su X, Zhang L, Liu CM, Liu H, Ma X and Xia H: Haplotype-based association of two SNPs in miR-323b with unexplained recurrent spontaneous abortion in a Chinese Han population. *J Cell Physiol* 233: 6001-6017, 2018.
44. Cheng D, Jiang S, Chen J, Li J, Ao L and Zhang Y: Upregulated long noncoding RNA linc00261 in pre-eclampsia and its effect on trophoblast invasion and migration via regulating miR-558/TIMP4 signaling pathway. *J Cell Biochem* 120: 13243-13253, 2019.
45. Yang X and Meng T: Long Noncoding RNA in Preeclampsia: transcriptional noise or innovative indicators? *Biomed Res Int* 2019: 5437621, 2019.
46. Zhou J, Wan J, Shu XE, Mao Y, Liu XM, Yuan X, Zhang X, Hess ME, Brünig JC and Qian SB: N(6)-Methyladenosine Guides mRNA alternative translation during integrated stress response. *Mol Cell* 69: 636-647.e7, 2018.
47. Bai Y, Rao H, Chen W, Luo X, Tong C and Qi H: Profiles of circular RNAs in human placenta and their potential roles related to preeclampsia. *Biol Reprod* 98: 705-712, 2018.
48. Han B, Chao J and Yao H: Circular RNA and its mechanisms in disease: From the bench to the clinic. *Pharmacol Ther* 187: 31-44, 2018.
49. Ou Y, Liu M, Zhu L, Deng K, Chen M, Chen H and Zhang J: The expression profile of circRNA and its potential regulatory targets in the placentas of severe pre-eclampsia. *Taiwan J Obstet Gynecol* 58: 769-777, 2019.
50. Zhang Y, Yang H, Zhang Y, Shi J, Chen R and Xiao X: CircSFXN1 regulates the behaviour of trophoblasts and likely mediates preeclampsia. *Placenta* 101: 115-123, 2020.
51. Deng N, Lei D, Huang J, Yang Z, Fan C and Wang S: Circular RNA expression profiling identifies hsa_circ_0011460 as a novel molecule in severe preeclampsia. *Pregnancy Hypertens* 17: 216-225, 2019.
52. Knöfler M and Pollheimer J: Human placental trophoblast invasion and differentiation: A particular focus on Wnt signaling. *Front Genet* 4: 190, 2013.
53. Shu C, Xu P, Han J, Han S and He J: Upregulation of circRNA hsa_circ_0008726 in pre-eclampsia inhibits trophoblast migration, invasion, and EMT by regulating miR-345-3p/RYBP Axis. *Reprod Sci* 29: 2829-2841, 2022.
54. Zhang S and Guo G: Circ_FURIN promotes trophoblast cell proliferation, migration and invasion in preeclampsia by regulating miR-34a-5p and TFAP2A. *Hypertens Res* 45: 1334-1344, 2022.
55. Ou Y, Zhu L, Wei X, Bai S, Chen M, Chen H and Zhang J: Circular RNA circ_0111277 attenuates human trophoblast cell invasion and migration by regulating miR-494/HTRA1/Notch-1 signal pathway in pre-eclampsia. *Cell Death Dis* 11: 479, 2020.
56. Sonderegger S, Husslein H, Leisser C and Knöfler M: Complex expression pattern of Wnt ligands and frizzled receptors in human placenta and its trophoblast subtypes. *Placenta* 28 (Suppl A): S97-S102, 2007.
57. Li X, Yu T, Zhai M, Wu Y, Zhao B, Duan C, Cheng H, Li H, Wei Z, Yang Y and Yu Z: Maternal cadmium exposure impairs placental angiogenesis in preeclampsia through disturbing thyroid hormone receptor signaling. *Ecotoxicol Environ Saf* 244: 114055, 2022.
58. Lu X, An L, Fan G, Zang L, Huang W, Li J, Liu J, Ge W, Huang Y, Xu J, *et al*: EGFR signaling promotes nuclear translocation of plasma membrane protein TSPAN8 to enhance tumor progression via STAT3-mediated transcription. *Cell Res* 32: 359-374, 2022.
59. Zhou RM, Shi LJ, Shan K, Sun YN, Wang SS, Zhang SJ, Li XM, Jiang Q, Yan B and Zhao C: Circular RNA-ZBTB44 regulates the development of choroidal neovascularization. *Theranostics* 10: 3293-3307, 2020.
60. Guan S, Li L, Chen WS, Jiang WY, Ding Y, Zhao LL, Shi YF, Wang J, Gui Q, Xu CC, *et al*: Circular RNA WHSC1 exerts oncogenic properties by regulating miR-7/TAB2 in lung cancer. *J Cell Mol Med* 25: 9784-9795, 2021.
61. Zhao G, Yuan H, Li Q, Zhang J, Guo Y, Feng T, Gu R, Ou D, Li S, Li K and Lin P: DDX39B drives colorectal cancer progression by promoting the stability and nuclear translocation of PKM2. *Signal Transduct Target Ther* 7: 275, 2022.
62. Gai S, Sun L, Wang H and Yang P: Circular RNA hsa_circ_0007121 regulates proliferation, migration, invasion, and epithelial-mesenchymal transition of trophoblast cells by miR-182-5p/PGF axis in preeclampsia. *Open Med (Wars)* 15: 1061-1071, 2020.
63. Lin Z, Tang X, Wan J, Zhang X, Liu C and Liu T: Functions and mechanisms of circular RNAs in regulating stem cell differentiation. *RNA Biol* 18: 2136-2149, 2021.
64. Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, Zhou Z, Shu G and Yin G: Wnt/ β -catenin signalling: Function, biological mechanisms, and therapeutic opportunities. *Signal Transduct Target Ther* 7: 3, 2022.
65. Du L, Kuang L, He F, Tang W, Sun W and Chen D: Mesenchymal-to-epithelial transition in the placental tissues of patients with preeclampsia. *Hypertens Res* 40: 67-72, 2017.
66. Wang F, Chen S, Wang J, Wang Y, Ruan F, Shu H, Zhu L and Man D: First trimester serum PAPP-A is associated with placenta accreta: A retrospective study. *Arch Gynecol Obstet* 303: 645-652, 2021.
67. Wang Y, Liu L, Wang J and Gao Y: Hsa_circ_0015382 is involved in the pathogenesis of preeclampsia by mediating THBS2 expression. *Am J Reprod Immunol* 90: e13760, 2023.
68. Hu D, Zhang P and Chen M: Database resources for functional circular RNAs. *Methods Mol Biol* 2284: 457-466, 2021.
69. Tan J, Zhong Z, Xu W and Zhang N: Overexpressed Hsa_circ_0001326 contributes to the decreased cell viability in SWAN71 Cells by Regulating MiR-186-5p/p27 Kip1 Axis. *Biol Pharm Bull* 44: 507-514, 2021.
70. Qian Y, Lu Y, Rui C, Qian Y, Cai M and Jia R: Potential significance of circular RNA in human placental tissue for patients with preeclampsia. *Cell Physiol Biochem* 39: 1380-1390, 2016.
71. Chen DB and Wang W: Human placental microRNAs and preeclampsia. *Biol Reprod* 88: 130, 2013.
72. Wang W, Feng L, Zhang H, Hachy S, Satohisa S, Laurent LC, Parast M, Zheng J and Chen DB: Preeclampsia up-regulates angiogenesis-associated microRNA (i.e., miR-17, -20a, and -20b) that target ephrin-B2 and EphB4 in human placenta. *J Clin Endocrinol Metab* 97: E1051-E1059, 2012.
73. Salzman J, Gawad C, Wang PL, Lacayo N and Brown PO: Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. *PLoS One* 7: e30733, 2012.
74. Kifle MM, Dahal P, Vatish M, Cerdeira AS and Ohuma EO: The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) biomarkers for predicting preeclampsia: A secondary analysis of data from the INSPIRE trial. *BMC Pregnancy Childbirth* 22: 520, 2022.
75. Senczuk-Sikora A, Krzyzanowski A, Kwiatek M and Senczuk M: Maternal serum concentration of placental growth factor (PlGF) and endothelial growth factor (VEGF) in pregnancies complicated by preeclampsia. *Ginek Pol* 78: 873-876, 2007 (In Polish).
76. Sezer SD, Kucuk M, Doger FK, Yuksel H, Odabasi AR, Turkmen MK, Cakmak BC, Omurlu IK and Kinan MG: VEGF, PlGF and HIF-1 α in placentas of early- and late-onset pre-eclamptic patients. *Gynecol Endocrinol* 29: 797-800, 2013.
77. Li J, Sun D, Pu W, Wang J and Peng Y: Circular RNAs in Cancer: Biogenesis, function, and clinical significance. *Trends Cancer* 6: 319-336, 2020.
78. Li X, Yang R, Xu Y and Zhang Y: Circ_0001438 participates in the pathogenesis of preeclampsia via the circ_0001438/miR-942/NLRP3 regulatory network. *Placenta* 104: 40-50, 2021.
79. Zhang N, Nan A, Chen L, Li X, Jia Y, Qiu M, Dai X, Zhou H, Zhu J, Zhang H and Jiang Y: Circular RNA circSATB2 promotes progression of non-small cell lung cancer cells. *Mol Cancer* 19: 101, 2020.
80. Zhu H, Niu X, Li Q, Zhao Y, Chen X and Sun H: Circ_0085296 suppresses trophoblast cell proliferation, invasion, and migration via modulating miR-144/E-cadherin axis. *Placenta* 97: 18-25, 2020.
81. Hansen TB, Kjems J and Damgaard CK: Circular RNA and miR-7 in cancer. *Cancer Res* 73: 5609-5612, 2013.

82. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, *et al*: Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature* 495: 333-338, 2013.
83. Karreth FA and Pandolfi PP: ceRNA cross-talk in cancer: When ce-bling rivalries go awry. *Cancer Discov* 3: 1113-1121, 2013.
84. Griggs LA, Hassan NT, Malik RS, Griffin BP, Martinez BA, Elmore LW and Lemmon CA: Fibronectin fibrils regulate TGF- β 1-induced Epithelial-Mesenchymal Transition. *Matrix Biol* 60-61: 157-175, 2017.
85. Panda AC: Circular RNAs Act as miRNA Sponges. *Adv Exp Med Biol* 1087: 67-79, 2018.
86. Liu Q, Zhang X, Hu X, Dai L, Fu X, Zhang J and Ao Y: Circular RNA Related to the Chondrocyte ECM Regulates MMP13 Expression by Functioning as a MiR-136 'Sponge' in human cartilage degradation. *Sci Rep* 6: 22572, 2016.
87. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK and Kjems J: Natural RNA circles function as efficient microRNA sponges. *Nature* 495: 384-388, 2013.
88. Xu H, Guo S, Li W and Yu P: The circular RNA Cdr1as, via miR-7 and its targets, regulates insulin transcription and secretion in islet cells. *Sci Rep* 5: 12453, 2015.
89. Zheng XB, Zhang M and Xu MQ: Detection and characterization of ciRS-7: A potential promoter of the development of cancer. *Neoplasma* 64: 321-328, 2017.
90. Wu J, Qi X, Liu L, Hu X, Liu J, Yang J, Yang J, Lu L, Zhang Z, Ma S, *et al*: Emerging Epigenetic Regulation of Circular RNAs in Human Cancer. *Mol Ther Nucleic Acids* 16: 589-596, 2019.
91. Geng HH, Li R, Su YM, Xiao J, Pan M, Cai XX and Ji XP: The Circular RNA Cdr1as promotes myocardial infarction by mediating the regulation of miR-7a on its target genes expression. *PLoS One* 11: e0151753, 2016.
92. Yu L, Gong X, Sun L, Zhou Q, Lu B and Zhu L: The Circular RNA Cdr1as Act as an oncogene in hepatocellular carcinoma through targeting miR-7 Expression. *PLoS One* 11: e0158347, 2016.
93. Pan H, Li T, Jiang Y, Pan C, Ding Y, Huang Z, Yu H and Kong D: Overexpression of Circular RNA ciRS-7 abrogates the tumor suppressive effect of miR-7 on Gastric Cancer via PTEN/PI3K/AKT signaling pathway. *J Cell Biochem* 119: 440-446, 2018.
94. Fan Y, Wang J, Jin W, Sun Y, Xu Y, Wang Y, Liang X and Su D: CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer. *Mol Cancer* 20: 25, 2021.
95. Holdt LM, Stahringer A, Sass K, Pichler G, Kulak NA, Wilfert W, Kohlmaier A, Herbst A, Northoff BH, Nicolaou A, *et al*: Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. *Nat Commun* 7: 12429, 2016.
96. Li H, Jin X, Liu B, Zhang P, Chen W and Li Q: CircRNA CBL11 suppresses cell proliferation by sponging miR-6778-5p in colorectal cancer. *BMC Cancer* 19: 826, 2019.
97. Abdelmohsen K, Panda AC, Munk R, Grammatikakis I, Dudekula DB, De S, Kim J, Noh JH, Kim KM, Martindale JL and Gorospe M: Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1. *RNA Biol* 14: 361-369, 2017.
98. Yang Q, Du WW, Wu N, Yang W, Awan FM, Fang L, Ma J, Li X, Zeng Y, Yang Z, *et al*: A circular RNA promotes tumorigenesis by inducing c-myc nuclear translocation. *Cell Death Differ* 24: 1609-1620, 2017.
99. Ou R, Lv J, Zhang Q, Lin F, Zhu L, Huang F, Li X, Li T, Zhao L, Ren Y and Xu Y: circAMOTL1 Motivates AMOTL1 expression to facilitate cervical cancer growth. *Mol Ther Nucleic Acids* 19: 50-60, 2020.
100. Chen CY and Sarnow P: Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs. *Science* 268: 415-417, 1995.
101. Zhang Y, Yang L and Chen LL: Life without A tail: New formats of long noncoding RNAs. *Int J Biochem Cell Biol* 54: 338-349, 2014.
102. Wang Y and Wang Z: Efficient backsplicing produces translatable circular mRNAs. *RNA* 21: 172-179, 2015.
103. Jang SK, Kräusslich HG, Nicklin MJ, Duke GM, Palmenberg AC and Wimmer E: A segment of the 5' nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during *in vitro* translation. *J Virol* 62: 2636-2643, 1988.
104. Godet AC, David F, Hantelys F, Tatin F, Lacazette E, Garmy-Susini B and Prats AC: IRES Trans-Acting Factors, Key Actors of the Stress Response. *Int J Mol Sci* 20: 924, 2019.
105. Macejak DG and Sarnow P: Internal initiation of translation mediated by the 5' leader of a cellular mRNA. *Nature* 353: 90-94, 1991.
106. Zhang M and Xin Y: Circular RNAs: A new frontier for cancer diagnosis and therapy. *J Hematol Oncol* 11: 21, 2018.
107. Qin M, Liu G, Huo X, Tao X, Sun X, Ge Z, Yang J, Fan J, Liu L and Qin W: Hsa_circ_0001649: A circular RNA and potential novel biomarker for hepatocellular carcinoma. *Cancer Biomark* 16: 161-169, 2016.
108. Zhang Y, Yang H, Zhang Y, Shi J and Chen R: circCRAMP1L is a novel biomarker of preeclampsia risk and may play a role in preeclampsia pathogenesis via regulation of the MSP/RON axis in trophoblasts. *BMC Pregnancy Childbirth* 20: 652, 2020.
109. Cao Y, Liu B, Cai L, Li Y, Huang Y, Zhou Y, Sun X, Yang W and Sun T: G9a promotes immune suppression by targeting the Fbxw7/Notch pathway in glioma stem cells. *CNS Neurosci Ther* 29: 2508-2521, 2023.
110. Yang Z, Hu N, Wang W, Hu W, Zhou S, Shi J, Li M, Jing Z, Chen C, Zhang X, *et al*: Loss of FBXW7 Correlates with Increased IDH1 expression in glioma and enhances IDH1-Mutant cancer cell sensitivity to radiation. *Cancer Res* 82: 497-509, 2022.
111. Yang Y, Gao X, Zhang M, Yan S, Sun C, Xiao F, Huang N, Yang X, Zhao K, Zhou H, *et al*: Novel Role of FBXW7 Circular RNA in repressing glioma tumorigenesis. *J Natl Cancer Inst* 110: 304-315, 2018.
112. Ye F, Gao G, Zou Y, Zheng S, Zhang L, Ou X, Xie X and Tang H: circFBXW7 Inhibits malignant progression by sponging miR-197-3p and Encoding a 185-aa protein in triple-negative breast cancer. *Mol Ther Nucleic Acids* 18: 88-98, 2019.
113. Liang WC, Wong CW, Liang PP, Shi M, Cao Y, Rao ST, Tsui SK, Waye MM, Zhang Q, Fu WM and Zhang JF: Translation of the circular RNA circ β -catenin promotes liver cancer cell growth through activation of the Wnt pathway. *Genome Biol* 20: 84, 2019.
114. Nejak-Bowen KN and Monga SP: Beta-catenin signaling, liver regeneration and hepatocellular cancer: Sorting the good from the bad. *Semin Cancer Biol* 21: 44-58, 2011.
115. Lu Y, Li Z, Lin C, Zhang J and Shen Z: Translation role of circRNAs in cancers. *J Clin Lab Anal* 35: e23866, 2021.
116. Glažar P, Papavasileiou P and Rajewsky N: circBase: A database for circular RNAs. *RNA* 20: 1666-1670, 2014.
117. He S and Tang S: WNT/ β -catenin signaling in the development of liver cancers. *Biomed Pharmacother* 132: 110851, 2020.
118. Zhong J, Wu X, Gao Y, Chen J, Zhang M, Zhou H, Yang J, Xiao F, Yang X, Huang N, *et al*: Circular RNA encoded MET variant promotes glioblastoma tumorigenesis. *Nat Commun* 14: 4467, 2023.
119. Zeng K, Peng J, Xing Y, Zhang L, Zeng P, Li W, Zhang W, Pan Z, Zhou C and Lin J: A positive feedback circuit driven by m(6)A-modified circular RNA facilitates colorectal cancer liver metastasis. *Mol Cancer* 22: 202, 2023.
120. Bokar JA, Shambaugh ME, Polayes D, Matera AG and Rottman FM: Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase. *RNA* 3: 1233-1247, 1997.
121. Ping XL, Sun BF, Wang L, Xiao W, Yang X, Wang WJ, Adhikari S, Shi Y, Lv Y, Chen YS, *et al*: Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. *Cell Res* 24: 177-189, 2014.
122. Agarwala SD, Blitzblau HG, Hochwagen A and Fink GR: RNA methylation by the MIS complex regulates a cell fate decision in yeast. *PLoS Genet* 8: e1002732, 2012.
123. Patil DP, Chen CK, Pickering BF, Chow A, Jackson C, Guttman M and Jaffrey SR: m(6)A RNA methylation promotes XIST-mediated transcriptional repression. *Nature* 537: 369-373, 2016.
124. Wen J, Lv R, Ma H, Shen H, He C, Wang J, Jiao F, Liu H, Yang P, Tan L, *et al*: Zc3h13 Regulates Nuclear RNA m(6)A Methylation and Mouse Embryonic Stem Cell Self-Renewal. *Mol Cell* 69: 1028-1038.e6, 2018.
125. Zhang Z and Wang XJ: N(6)-Methyladenosine mRNA Modification: From modification site selectivity to neurological functions. *Acc Chem Res* 56: 2992-2999, 2023.
126. Meyer KD, Patil DP, Zhou J, Zinoviev A, Skabkin MA, Elemento O, Pestova TV, Qian SB and Jaffrey SR: 5' UTR m(6)A Promotes Cap-Independent Translation. *Cell* 163: 999-1010, 2015.
127. Su M, Xiao Y, Ma J, Tang Y, Tian B, Zhang Y, Li X, Wu Z, Yang D, Zhou Y, *et al*: Circular RNAs in Cancer: Emerging functions in hallmarks, stemness, resistance and roles as potential biomarkers. *Mol Cancer* 18: 90, 2019.

128. Harland R and Misher L: Stability of RNA in developing *Xenopus* embryos and identification of a destabilizing sequence in TFIIB messenger RNA. *Development* 102: 837-852, 1988.
129. Zhang M, Huang N, Yang X, Luo J, Yan S, Xiao F, Chen W, Gao X, Zhao K, Zhou H, *et al*: A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis. *Oncogene* 37: 1805-1814, 2018.
130. Fu Y, Wang Z, Luo C, Wang Y, Wang Y, Zhong X and Zheng H: Downregulation of CXCR4 Finger Protein 4 Leads to a Tamoxifen-resistant phenotype in breast cancer cells through activation of the Wnt/beta-catenin Pathway. *Transl Oncol* 13: 423-440, 2020.
131. Yang Q, Wu J, Zhao J, Xu T, Zhao Z, Song X and Han P: Circular RNA expression profiles during the differentiation of mouse neural stem cells. *BMC Syst Biol* 12 (Suppl 8): 128, 2018.
132. Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao L, Zhang Y, Wu YM, Dhanasekaran SM, Engelke CG, Cao X, *et al*: The landscape of circular RNA in Cancer. *Cell* 176: 869-881.e13, 2019.
133. Tan H, Gan L, Fan X, Liu L and Liu S: Diagnostic value of circular RNAs as effective biomarkers for cancer: A systematic review and meta-analysis. *Onco Targets Ther* 12: 2623-2633, 2019.
134. Wang J, Zhao X, Wang Y, Ren F, Sun D, Yan Y, Kong X, Bu J, Liu M and Xu S: circRNA-002178 act as a ceRNA to promote PDL1/PD1 expression in lung adenocarcinoma. *Cell Death Dis* 11: 32, 2020.
135. Cui L, Shi M, Meng X, Qian J and Wang S: Identification of m6A modification regulated by dysregulated circRNAs in decidua of recurrent pregnancy loss. *Curr Issues Mol Biol* 45: 8767-8779, 2023.
136. Inoue T, Watanabe T and Tanaka Y: Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy. *Clin Mol Hepatol* 29: 851-868, 2023.
137. Shafabakhsh R, Mirhosseini N, Chaichian S, Moazzami B, Mahdizadeh Z and Asemi Z: Could circRNA be a new biomarker for pre-eclampsia? *Mol Reprod Dev* 86: 1773-1780, 2019.
138. Zhang Y, Yang H, Zhang Y, Shi J and Long Y: A Novel Circular RNA CircBRAP may be used as an early predictor of preeclampsia and its potential mechanism. *Reprod Sci* 29: 2565-2579, 2022.
139. Zhang X, Qiu S, Luo P, Zhou H, Jing W, Liang C and Tu J: Down-regulation of hsa_circ_0001649 in hepatocellular carcinoma predicts a poor prognosis. *Cancer Biomark* 22: 135-142, 2018.
140. Zhou W, Wang H, Wu X, Long W, Zheng F, Kong J and Yu B: The profile analysis of circular RNAs in human placenta of preeclampsia. *Exp Biol Med (Maywood)* 243: 1109-1117, 2018.
141. Zhang YG, Yang HL, Long Y and Li WL: Circular RNA in blood corpuscles combined with plasma protein factor for early prediction of pre-eclampsia. *BJOG* 123: 2113-2118, 2016.
142. Chen CK, Cheng R, Demeter J, Chen J, Weingarten-Gabbay S, Jiang L, Snyder MP, Weissman JS, Segal E, Jackson PK and Chang HY: Structured elements drive extensive circular RNA translation. *Mol Cell* 81: 4300-4318.e13, 2021.
143. Li Y, Shen Z, Jiang X, Wang Y, Yang Z, Mao Y, Wu Z, Li G and Chen H: Mouse mesenchymal stem cell-derived exosomal miR-466f-3p reverses EMT process through inhibiting AKT/GSK3 β pathway via c-MET in radiation-induced lung injury. *J Exp Clin Cancer Res* 41: 128, 2022.
144. Dai XM, Zhang YH, Lin XH, Huang XX, Zhang Y, Xue CR, Chen WN, Ye JX, Lin XJ and Lin X: SIK2 represses AKT/GSK3 β / β -catenin signaling and suppresses gastric cancer by inhibiting autophagic degradation of protein phosphatases. *Mol Oncol* 15: 228-245, 2021.
145. Yang B, Li L, Tong G, Zeng Z, Tan J, Su Z, Liu Z, Lin J, Gao W, Chen J, *et al*: Circular RNA circ_001422 promotes the progression and metastasis of osteosarcoma via the miR-195-5p/FGF2/PI3K/Akt axis. *J Exp Clin Cancer Res* 40: 235, 2021.
146. Liu Y, Qi X, Donnelly L, Elghobashi-Meinhardt N, Long T, Zhou RW, Sun Y, Wang B and Li X: Mechanisms and inhibition of Porcupine-mediated Wnt acylation. *Nature* 607: 816-822, 2022.
147. Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O, Fatica A, Santini T, Andronache A, Wade M, *et al*: Circ-ZNF609 Is a Circular RNA that can be translated and functions in myogenesis. *Mol Cell* 66: 22-37.e9, 2017.
148. Yang HL, Zhang HZ, Meng FR, Han SY and Zhang M: Differential expression of microRNA-411 and 376c is associated with hypertension in pregnancy. *Braz J Med Biol Res* 52: e7546, 2019.
149. Wang Z, Sun A, Yan A, Yao J, Huang H, Gao Z, Han T, Gu J, Li N, Wu H and Li K: Circular RNA MTCL1 promotes advanced laryngeal squamous cell carcinoma progression by inhibiting C1QB ubiquitin degradation and mediating beta-catenin activation. *Mol Cancer* 21: 92, 2022.
150. Wang J, Hu K, Cai X, Yang B, He Q, Wang J and Weng Q: Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis. *Acta Pharm Sin B* 12: 18-32, 2022.
151. Liu B, Zhao N, Zhou Y, Lu Y, Chen W, Huang Z, Wang D, Xu Y, Wai Ping Yam J and Cui Y: Circular RNA circ_ABCB10 in cancer. *Clin Chim Acta* 518: 93-100, 2021.
152. Barzegar Behrooz A, Talaie Z, Jusheghani F, Los MJ, Klonisch T and Ghavami S: Wnt and PI3K/Akt/mTOR survival pathways as therapeutic targets in glioblastoma. *Int J Mol Sci* 23: 1353, 2022.
153. Liu Z, Zhou Y, Liang G, Ling Y, Tan W, Tan L, Andrews R, Zhong W, Zhang X, Song E and Gong C: Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p. *Cell Death Dis* 10: 55, 2019.
154. Li X, Li C, Liu Z, Ni W, Yao R, Xu Y, Quan R, Zhang M, Li H, Liu L and Hu S: Circular RNA circ-FoxO3 inhibits myoblast cells differentiation. *Cells* 8: 616, 2019.



Copyright © 2024 Jiang et al. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.